Cargando…

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency

Background and aim: The value of the forced expiratory volume in one second (FEV(1)) is useful in the diagnosis and prognosis of chronic obstructive pulmonary disease (COPD). Previous studies on lung function in individuals with severe alpha-1 antitrypsin deficiency (AATD) have shown a variable annu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiller, Adriana-Maria, Piitulainen, Eeva, Jehpsson, Lars, Tanash, Hanan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536893/
https://www.ncbi.nlm.nih.gov/pubmed/31213789
http://dx.doi.org/10.2147/COPD.S195847
_version_ 1783421873148657664
author Hiller, Adriana-Maria
Piitulainen, Eeva
Jehpsson, Lars
Tanash, Hanan
author_facet Hiller, Adriana-Maria
Piitulainen, Eeva
Jehpsson, Lars
Tanash, Hanan
author_sort Hiller, Adriana-Maria
collection PubMed
description Background and aim: The value of the forced expiratory volume in one second (FEV(1)) is useful in the diagnosis and prognosis of chronic obstructive pulmonary disease (COPD). Previous studies on lung function in individuals with severe alpha-1 antitrypsin deficiency (AATD) have shown a variable annual decline in FEV(1) (∆FEV(1)). The aim of this study was to analyze ∆FEV(1) and to identify risk factors for ∆FEV(1) in individuals with severe AATD. Material and methods: Data on smoking habits, symptoms, results of lung function tests and exacerbations were obtained from the Swedish AATD Register and the Swedish National Patient Register (SNPR). The ∆FEV(1) was analyzed by random-effects modeling and adjusted for age and FEV(1) at baseline. Results: One hundred and four (9%) current smokers, 539 (48%) ex-smokers and 489 (43%) never-smokers were included in the study and followed-up from 1991 to 2016. A total of 584 (52%) individuals with severe AATD had COPD at inclusion. The median (IQR) annual severe exacerbation rate was 0.66 (1.4). The adjusted mean ∆FEV(1) was significantly higher in the current smokers compared with the ex-smokers and never-smokers (70 [95% CI 56–83] vs 42 [95% CI 36–48] and 32 [95% CI 25–38) mL·yr(−1)], in the middle–aged individuals compared with the young individuals (48 [95% CI 41–55] vs 32 [95% CI 18–45] mL·yr(−1)), in the individuals with respiratory symptoms at inclusion compared with the asymptomatic individuals (46 [95% CI 40–52] vs 30 [95% CI 22–38]mL·yr(−1)), and in the individuals with frequent exacerbations compared with those with infrequent exacerbations (57 [95% CI 47–68] vs 27 [95% CI 17–37] mL·yr(−1)). Conclusion: Active smoking, age, respiratory symptoms at baseline and repeated severe exacerbations of COPD are factors associated with an accelerated decline of lung function in individuals with severe AATD.
format Online
Article
Text
id pubmed-6536893
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65368932019-06-18 Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency Hiller, Adriana-Maria Piitulainen, Eeva Jehpsson, Lars Tanash, Hanan Int J Chron Obstruct Pulmon Dis Original Research Background and aim: The value of the forced expiratory volume in one second (FEV(1)) is useful in the diagnosis and prognosis of chronic obstructive pulmonary disease (COPD). Previous studies on lung function in individuals with severe alpha-1 antitrypsin deficiency (AATD) have shown a variable annual decline in FEV(1) (∆FEV(1)). The aim of this study was to analyze ∆FEV(1) and to identify risk factors for ∆FEV(1) in individuals with severe AATD. Material and methods: Data on smoking habits, symptoms, results of lung function tests and exacerbations were obtained from the Swedish AATD Register and the Swedish National Patient Register (SNPR). The ∆FEV(1) was analyzed by random-effects modeling and adjusted for age and FEV(1) at baseline. Results: One hundred and four (9%) current smokers, 539 (48%) ex-smokers and 489 (43%) never-smokers were included in the study and followed-up from 1991 to 2016. A total of 584 (52%) individuals with severe AATD had COPD at inclusion. The median (IQR) annual severe exacerbation rate was 0.66 (1.4). The adjusted mean ∆FEV(1) was significantly higher in the current smokers compared with the ex-smokers and never-smokers (70 [95% CI 56–83] vs 42 [95% CI 36–48] and 32 [95% CI 25–38) mL·yr(−1)], in the middle–aged individuals compared with the young individuals (48 [95% CI 41–55] vs 32 [95% CI 18–45] mL·yr(−1)), in the individuals with respiratory symptoms at inclusion compared with the asymptomatic individuals (46 [95% CI 40–52] vs 30 [95% CI 22–38]mL·yr(−1)), and in the individuals with frequent exacerbations compared with those with infrequent exacerbations (57 [95% CI 47–68] vs 27 [95% CI 17–37] mL·yr(−1)). Conclusion: Active smoking, age, respiratory symptoms at baseline and repeated severe exacerbations of COPD are factors associated with an accelerated decline of lung function in individuals with severe AATD. Dove 2019-05-23 /pmc/articles/PMC6536893/ /pubmed/31213789 http://dx.doi.org/10.2147/COPD.S195847 Text en © 2019 Hiller et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Hiller, Adriana-Maria
Piitulainen, Eeva
Jehpsson, Lars
Tanash, Hanan
Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
title Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
title_full Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
title_fullStr Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
title_full_unstemmed Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
title_short Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
title_sort decline in fev(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536893/
https://www.ncbi.nlm.nih.gov/pubmed/31213789
http://dx.doi.org/10.2147/COPD.S195847
work_keys_str_mv AT hilleradrianamaria declineinfev1andhospitalizedexacerbationsinindividualswithseverealpha1antitrypsindeficiency
AT piitulaineneeva declineinfev1andhospitalizedexacerbationsinindividualswithseverealpha1antitrypsindeficiency
AT jehpssonlars declineinfev1andhospitalizedexacerbationsinindividualswithseverealpha1antitrypsindeficiency
AT tanashhanan declineinfev1andhospitalizedexacerbationsinindividualswithseverealpha1antitrypsindeficiency